BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 14693733)

  • 1. Comprehensive assessment of candidate genes and serological markers for the detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Jewett MA; Emami M; Vesprini D; Chu W; Ho M; Sweet J; Evans A; Toi A; Pollak M; Narod SA
    Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1429-37. PubMed ID: 14693733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association studies of serum prostate-specific antigen levels and the genetic polymorphisms at the androgen receptor and prostate-specific antigen genes.
    Xu J; Meyers DA; Sterling DA; Zheng SL; Catalona WJ; Cramer SD; Bleecker ER; Ohar J
    Cancer Epidemiol Biomarkers Prev; 2002 Jul; 11(7):664-9. PubMed ID: 12101115
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility of incorporating genetic variants for the early detection of prostate cancer.
    Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
    Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
    Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
    Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls.
    Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S
    Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
    Thompson IM; Pauler Ankerst D; Chi C; Goodman PJ; Tangen CM; Lippman SM; Lucia MS; Parnes HL; Coltman CA
    J Clin Oncol; 2007 Jul; 25(21):3076-81. PubMed ID: 17634486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Histological diagnosis of prostate cancer in Korean men aged 70-79 years.
    Shim HB; Lee SE; Park HK; Ku JH
    Jpn J Clin Oncol; 2007 Oct; 37(10):782-7. PubMed ID: 17913831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of genetic markers to determine risk for prostate cancer at prostate biopsy.
    Nam RK; Zhang WW; Jewett MA; Trachtenberg J; Klotz LH; Emami M; Sugar L; Sweet J; Toi A; Narod SA
    Clin Cancer Res; 2005 Dec; 11(23):8391-7. PubMed ID: 16322300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum measurements of testosterone, insulin-like growth factor 1, and insulin-like growth factor binding protein-3 in the diagnosis of prostate cancer among Korean men.
    Hong SK; Han BK; Jeong JS; Jeong SJ; Moon KH; Byun SS; Lee SE
    Asian J Androl; 2008 Mar; 10(2):207-13. PubMed ID: 18097534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of prostate cancer at different levels of serum prostate-specific antigen (PSA) and different free: total PSA ratios in a consecutive series of men referred for prostate biopsies.
    Rydén L; Egevad L; Ekman P; Hellström M
    Scand J Urol Nephrol; 2007; 41(4):302-7. PubMed ID: 17763221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate cancer risk with positive family history, normal prostate examination findings, and PSA less than 4.0 ng/mL.
    Canby-Hagino E; Hernandez J; Brand TC; Troyer DA; Higgins B; Ankerst DP; Thompson IM; Leach RJ; Parekh DJ
    Urology; 2007 Oct; 70(4):748-52. PubMed ID: 17991549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB; Carver BS; Caldito G; Venable DD; Eastham JA
    Urology; 2005 Oct; 66(4):803-7. PubMed ID: 16230142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study.
    Seo HK; Chung MK; Ryu SB; Lee KH;
    Urology; 2007 Dec; 70(6):1109-12. PubMed ID: 18158028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
    Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
    Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z; Jieming L; Su L; Wenlu S
    J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.